Intestinal Microbial Metabolites in Ankylosing Spondylitis

被引:15
作者
Scalise, Giuseppe [1 ]
Ciancio, Antonio [1 ]
Mauro, Daniele [1 ]
Ciccia, Francesco [1 ]
机构
[1] Univ Campania L Vanvitelli, Dept Precis Med, Rheumatol Unit, I-80138 Naples, Italy
关键词
ankylosing spondylitis; immunometabolism; microbial metabolism; microbiota; SCFA; dysbiosis; interleukin; 17; CHAIN FATTY-ACIDS; ARYL-HYDROCARBON RECEPTOR; BUTYRATE-PRODUCING BACTERIA; PROTEIN-COUPLED RECEPTOR; REGULATORY T-CELLS; GUT MICROBIOTA; PERIPHERAL-BLOOD; BARRIER FUNCTION; PPAR-GAMMA; TRYPTOPHAN-METABOLISM;
D O I
10.3390/jcm10153354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ankylosing spondylitis (AS) is a chronic inflammatory disease characterized by inflammation of axial joints and the pelvis. It is known that intestinal dysbiosis may exert direct pathogenic effects on gut homeostasis and may act as a triggering factor for the host innate immune system to activate and cause inflammation in extraintestinal sites in the so-called "gut-joint axis", contributing to AS pathogenesis. However, although the intestinal microbiota's influence on the clinical manifestation of AS is widely accepted, the mechanisms mediating the cross-talk between the intestinal lumen and the immune system are still not completely defined. Recent evidence suggests that the metabolism of microbial species may be a source of metabolites and small molecules participating in the complex network existing between bacteria and host cells. These findings may give inputs for further research of novel pharmacological targets and pave the way to applying dietary interventions to prevent the onset and ameliorate the clinical presentation of the disease. In this review, we discuss the role of some of the biological mediators of microbial origin, with a particular focus on short-chain fatty acids, tryptophan and vitamin B derivatives, and their role in barrier integrity and type 3 immunity in the context of AS.
引用
收藏
页数:20
相关论文
共 50 条
[41]   Diet-derived microbial metabolites in health and disease [J].
Roager, H. M. ;
Dragsted, L. O. .
NUTRITION BULLETIN, 2019, 44 (03) :216-227
[42]   Thalidomide in ankylosing spondylitis [J].
Huang, F ;
Wei, JCC ;
Breban, M .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (06) :S158-S161
[43]   Osteoporosis in ankylosing spondylitis [J].
Magrey M. ;
Khan M.A. .
Current Rheumatology Reports, 2010, 12 (5) :332-336
[44]   Ankylosing spondylitis and kinesiophobia [J].
Ertem, Ugur .
PEERJ, 2025, 13
[45]   Diagnosing ankylosing spondylitis [J].
Elyan, Mazen ;
Khan, Muhammad Asim .
JOURNAL OF RHEUMATOLOGY, 2006, 33 :12-23
[46]   Mortality in ankylosing spondylitis [J].
Zochling, J. ;
Braun, J. .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (05) :S80-S84
[47]   The burden of ankylosing spondylitis [J].
Boonen, Annelies ;
van der Linden, Sjef M. .
JOURNAL OF RHEUMATOLOGY, 2006, 33 :4-11
[48]   Genetics of ankylosing spondylitis [J].
Brown, MA ;
Wordsworth, BP ;
Reveille, JD .
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2002, 20 (06) :S43-S49
[49]   Immunogenetic of ankylosing spondylitis [J].
Toussirot, E. ;
Wendling, D. .
REVUE DE MEDECINE INTERNE, 2006, 27 (10) :762-771
[50]   Celecoxib and ankylosing spondylitis [J].
Calin, Andrei .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2008, 4 (03) :339-349